DocWire News Editors

DocwireNews

A group of researchers from Imperial College in London have recently conducted a study in which CRISPR-Cas9 genomic editing was used to eliminate malaria-infected mosquitoes. In their findings published in Nature Biotechnology, scientists were able to eradicate a controlled population of mosquitoes in as few as 7 reproductive generations. The project was funded in part by the Bill and Melinda Gates Foundation, the UK&rsquo;s Biotechnology and Biological Sciences Research Council, and the Massachusetts General Hospital program.Specifically, the researchers target what they denote as a &ldquo;doublesex&rdquo; gene that is unique to the mosquito&rsquo;s gender determination. Unlike the male version of the gene, the female version contains a unique exon that the researchers utilized to eradicate females in the population. By doing so the team effectively reduced the population composition to consist solely of males, causing cessation of reproduction.Using CRISPR target disruption of this exon region in the mosquito genome, the researchers blocked the formation of complexes that had no effect on male growth and fertility but led to sterility in the females who carried two copies of the gene. The researchers report that this process allowed led to &ldquo;100% prevalence within 7&ndash;11 generations while progressively reducing egg production to the point of total population collapse.&rdquo; These modified females displayed both male and female characteristics, rendering them unable to bite and lay eggs.The UK researchers created these genetically modified mosquitoes specifically for use as a weapon against malaria. 216 million cases of malaria were documented in 2016, as per World Health Organization data, and 445,000 of these cases resulted in death. In addition, most fatalities resulting from malaria are represented by children under the age of five. The need for preventative measures against the parasite is eminent, and with their new research findings, the Imperial research team is optimistic that they could be developing a potential candidate.&ldquo;We are very excited,&rdquo; said research leader Andrea Crisanti, a professor of molecular parasitology at Imperial College London. &ldquo;This is a game-changer. This is a completely new era in genetics.&rdquo; Kevin Esvelt, MIT evolutionary engineer and genetic researcher who was not part of the research confers, describing the paper to be &ldquo;extraordinary&rdquo;.<blockquote class="twitter-tweet" data-lang="en">
Using Crispr, researchers were able to wipe out an entire population of malaria-touting mosquitoes <a href="https://t.co/O1GTI3T4wR">https://t.co/O1GTI3T4wR</a>
&mdash; WIRED (@WIRED) <a href="https://twitter.com/WIRED/status/1044273527875162112?ref_src=twsrc%5Etfw">September 24, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Sources: <a href="https://www.nature.com/articles/nbt.4245">Nature Biotechnologies</a>,&nbsp;<a href="http://www.foxnews.com/science/2018/09/25/malaria-breakthrough-disease-carrying-mosquitoes-wiped-out-in-major-lab-experiment.html">Fox News</a>, <a href="https://www.npr.org/sections/goatsandsoda/2018/09/24/650501045/mosquitoes-genetically-modified-to-crash-species-that-spreads-malaria">NPR</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

UK Researchers Use CRISPR Genome Editing to Eliminate Malaria in Study

Future of Medicine

A group of researchers from Imperial College in London have recently conducted a study in which CRISPR-Cas9 genomic editing was used to eliminate malaria-infected mosquitoes. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe